Also known as: Rigel
The FDA has approved Pfizer's BRAFTOVI for BRAF V600E metastatic colorectal cancer and VEPPANU for ESR1 mutated breast cancer. The oncolytic virus cancer therapy pipeline expands with over 120 companies developing 125+ drugs. Positive late-stage data for other Pfizer oncology programs was also reported.
Monthly patent reviews from April through December 2025 highlight notable drug discovery IP disclosures across targeted protein degradation, small molecule modulators, and emerging therapeutic targets in oncology, immunology, and neurology.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07471841 |
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax |
NOT_YET_RECRUITING | PHASE2 |
